<DOC>
	<DOCNO>NCT02296853</DOCNO>
	<brief_summary>This study evaluate single-dose pharmacokinetics tenofovir alafenamide ( TAF ) 's metabolite tenofovir ( TFV ) along safety tolerability TAF participant normal hepatic function severe hepatic impairment .</brief_summary>
	<brief_title>Pharmacokinetics Tenofovir Alafenamide Adults With Normal Hepatic Function Severe Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Screening lab within defined threshold Creatinine clearance must â‰¥ 60 mL/min Females pregnant nursing male pregnant partner Infection hepatitis B virus ( HBV ) HIV History clinically significant illness ( include psychiatric cardiac ) medical disorder may interfere participant treatment and/or adherence protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Severe Hepatic Impairment</keyword>
</DOC>